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Acetate metabolism and bicarbonate generation during hemodialysis:
10 years of observation. The capacity of chronically hemodialyzed
patients to metabolize acetate during coventional hemodialysis was
evaluated using a retrospective study in 219 patients dialyzed for up to
ten years under similar dialysis conditions. For each patient, and using
all available data, a regression line relating the changes of plasma total
CO2 during dialysis as a function of the pre-dialysis value was calcu-
lated. The intercept of this function indicates the plasma concentration
where the losses of bicarbonate in the dialysate is matched by the
generation of bicarbonate arising from the metabolism of acetate. This
value therefore represents an individual index of the capacity of each
patient to metabolize acetate. A value for this index smaller than 18.0
mM was considered abnormal. It was shown that around 10% of
chronically hemodialyzed patients are clearly unable to metabolize
acetate optimally. This defect is not related to the duration of dialysis,
body weight or quality of hemodialysis treatments but is strongly
related to sex, 19 of the 22 "acetate intolerant" patients being women.
In a prospective study, all the 60 patients of the same population
undergoing active dialysis were studied, and this index identified 12
abnormal (11 women, I man) patients and 48 normal patients. Plasma
acetate measured at the end their dialysis treatments were significantly
higher in abnormal than in normal patients. It is concluded: 1) that this
index is useful to identify the patients unable to metabolize acetate
optimally; 2) that only around 10% of hemodialyzed patients present a
severe problem when dialyzed against acetate and should be dialyzed
against bicarbonate; 3) that dialysis against acetate does not fully
correct the metabolic acidosis even in "normal" patients.
During conventional hemodialysis, bicarbonate is transferred
out of the patient's blood into the dialysate along a chemical
gradient. In early procedures, bicarbonate was added to the
dialysis bath in order to prevent this loss and to induce a net
gain of bicarbonate into the patient. However, for reasons of
biochemical stability of the bath, bicarbonate was soon re-
placed in the dialysate by acetate [1]. In the body, acetate is
rapidly metabolized (mostly through oxidation [2—4]) generating
one bicarbonate for each acetate used. Because acetate is not as
permeant as bicarbonate [5] a relatively high concentration (35
to 40 mM) must be present in the bath in order to obtain a
mass—transfer of acetate into the patient slightly above the
mass—transfer of bicarbonate into the dialysate [1, 5]. Further-
more, enough acetate must be provided to replace the bicar-
bonate lost as organic anions and to compensate for the
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interdialyctic metabolic loss of bicarbonate [2, 4]. Clearly the
rate of transfer and metabolism of acetate plays a critical role in
maintaining the plasma bicarbonate concentration during
hemodialysis.
It was soon established that the rate of acetate transfer
obtained with conventional hemodialysis was close to the
maximal rate of acetate oxidation in man [2—6]. If the acetate
transfer exceeds this rate [6—8] or if the metabolic disposal of
acetate is abnormally small in a given subject [9], the generation
of bicarbonate will not keep pace with the rate of acetate entry
in the body fluids and acetate will accumulate in the blood. The
rate of acetate metabolism may then be insufficient to counter-
balance the loss of bicarbonate during dialysis. As a result,
plasma bicarbonate concentration will fall until a steady—state is
reached where the reduced outfiux of bicarbonate will be offset
by the existing rate of acetate metabolism. At high blood
concentration, acetate may exert pharmacological effects not
present at low concentration, causing vascular [10—12] and
other effects [13—15] which may cause various symptoms.
Clinical situations with intolerance to dialysis, high plasma
acetate and low plasma bicarbonate concentrations per dialysis
have been attributed to a syndrome of "acetate intolerance"
[9].
It must be noted that this syndrome may be observed in
patients with normal acetate metabolism but with acetate trans-
fer exceeding their maximal metabolic capacity (small patients
[6—81) as well as in patients with an abnormally low rate of
acetate metabolism. Therefore this syndrome indicates non-
optimal dialysis conditions for a given patient, related or not to
a specific biochemical anomaly of acetate metabolism. It ap-
pears useful to be able to evaluate in a simple fashion the
capacity of a given patient to metabolize acetate optimally
under a given dialysis set—up.
This study shows that it is possible to identify patients unable
to metabolize the acetate load imposed by dialysis optimally by
using a simple procedure. The rational of this procedure is as
follows: an individual index of acetate metabolism is obtained
by measuring the plasma bicarbonate concentration supported
by acetate metabolism when no net gain or loss of plasma
bicarbonate occurs during dialysis. This value is specific for
each patient under a given condition of dialysis and is directly
related to his capacity to metabolize acetate. This critical
concentration can be estimated by examining the net gain or
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loss of bicarbonate (-HCO3) per dialysis as a function of the
initial plasma bicarbonate; indeed, by taking advantage of the
spontaneous variation of initial plasma bicarbonate with time
and by using the measurements of several dialysis, a line can be
calculated with intercept (-HCO3 0) providing an estimation
of this point of equilibrium. Alternatively if equilibrium is
reached per dialysis, the plasma bicarbonate concentration at
the end of hemodialysis may also provide an estimation of this
value.
We have used this approach to examine the capacity to
metabolize a standard acetate load in a large population of
chronically hemodialyzed patients treated at Hospital
Notre—Dame in Montreal between 1974 and 1984. This retro-
spective study was possible because the clinical and biochem-
ical data of all patients dialysed in our institution since 1974 are
stored on computer files. In order to validate our approach by a
prospective study, we have also correlated the end—dialysis
blood acetate concentration of all patients under active dialysis
in our institution with their indexes of acetate metabolism as
described above.
The following questions were specifically examined: 1) what
is the incidence of patients presenting an inappropriate load or
metabolism of acetate in a large population of patients chroni-
cally hemodialyzed using conventional procedures? 2) Is the
incapacity to maintain normal plasma bicarbonate per dialysis
related to the duration of hemodialysis? 3) Is this anomaly
linked with the quality of dialysis (blood concentration of BUN,
creatinine, etc.)? 4) Does the measurement of an abnormally
low end—dialysis plasma bicarbonate correlate with a high
blood—acetate concentration.
Methods
Retrospective study
Population. The computerized records of all patients (N =
366) hemodialyzed in Notre—Dame Hospital, Montreal, be-
tween 1974 and 1984 were examined. Patients dialyzed for less
than 10 times, or having less than ten measurements of total
CO2 before and after dialysis (N = 147) were excluded, leaving
219 chronically dialyzed patients in the study. These patients
were dialyzed for periods ranging from three months to more
than 10 years. All patients were dialyzed with comparable
conditions (filter surface: 1.2 to 1.4 m2; filter membrane: cellu-
lose, cuprophane or polyacrylonitrile; dialysate: glucose—free
solution containing acetate [35 to 38 mM]; frequency of dialysis:
two or three dialysis a week). All measurements of blood
chemistry were performed from samples obtained from the
arterial line of the dialyzer.
Estimation of the "equilibrium" plasma bicarbonate concen-
tration. For each patient, and using all the available data, the
net gain or loss of total CO2 per dialysis ( total C02, X axis)
was plotted as a function of the pre-dialysis total CO2 (Y axis).
The relation between these points (Y = A + BX) was calculated
by the least squares method. The intercept of this function (A)
indicates the plasma bicarbonate concentration observed when
no change of total CO2 occurs per-dialysis (i-CO2 =0), that is,
the "equilibrium" plasma conceiiration supported by acetate
metabolism (Figure IA). The post-dialysis plasma total CO2
concentration (P) was taken as another estimation of this
equilibrium concentration.
Total CO2 mM
Fig. 1. A. The theoretical change of I.-CO2 expected during
hemodialysis when the initial plasma total CO2 is below (C) or above (B)
the "equilibrium" concentration, that is, the concentration where the
metabolic generation of bicarbonate equals the rate of loss through
dialysis (i-CO2 = 0). This point is defined either by the intercept with
the ordinate (A) (line of no change of bicarbonate) or by the bicarbonate
concentration at the end of dialysis (P). B. This relation for patient
"intolerant" to acetate.
Indeed both the intercept of the z C02/CO2 graph (A) and the
post-dialysis total CO2 concentration (P) were found to be
tightly correlated (intercept = 0.56; slope = 0.90; r 0.81)
indicating that a steady state (bicarbonate generation = bicar-
bonate loss) occurs per dialysis. However, it should be noted
that the accuracy of calculation of the intercept (A) depends on
the tightness of the CO2/C02 relation which may be inade-
quate in some cases. Therefore a patient was considered
"abnormal" only if both the parameters (A) and (P) were
considered abnormal. If both indexes are smaller than 18.0 mM
in a given patient, one can assume that his rate of acetate
metabolism is unable to compensate for the dialyctic losses of
bicarbonate occurring when the plasma bicarbonate concentra-
tion rises above 18.0 mM. Also, the incidence (I) of hemo-
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dialysis where a net loss of bicarbonate occurred was calculated
for each patient.
Using these four parameters, the population studied was
divided into five groups:
Groups
I Acetate tolerant
II Acetate tolerant
III Acetate tolerant
IV Uncertain tolerance
V Acetate intolerant
% of
Dialysis
with Post-
bicar- dialysis
bonate Intercept total CO2
i..CO2 loss (I) (A) (P)
+ <10% >18.0 mM >18.0 mM
+ >10% >18.0mM >18.0mM
- >10% >18.0 mri >18.0 mM
+
-
>10%
>10%
<16.5mM
<16.5mM
>18.0mM
<16.5mM
Patients of group I will gain bicarbonate in more than 90% of
their dialysis treatments, a finding expected if their pre-dialysis
bicarbonate concentration is significantly lower than the equi-
librium value (Fig. 1A, point C). Patients of group II will also
gain bicarbonate per dialysis, but occasionally (more than 10%
of hemodialysis) a net loss will be observed: these patients
would present a total pre-dialysis CO2 closer to (often below,
occasionally above) the equilibrium value (Fig. 1A, point A).
Patients of group III start their treatment with plasma total CO2
above the equilibrium value and therefore will regularly lose
bicarbonate per dialysis. In patients of groups I, II and III both
estimations of the equilibrium total CO2 concentration (A and
P) are above 18.0 m. These patients are capable to offset their
bicarbonate losses through rapid acetate metabolism and are
thus considered "acetate—tolerant". Patients of group IV have
an intercept value lower than 18.0 m, but a total CO2 higher
than around 18 m at the end of dialysis; both parameters A
and P do not agree. This discordance is attributable to inaccu-
racies in the calculation of the intercept A because of excessive
variations in the points (low correlation coefficient of the
C02/CO2 relation). Since the total CO2 approaches or exceeds
18.0 m at the end of dialysis, these patients were also
considered normal. Only patients of group V regularly lose
bicarbonate and are unable to maintain plasma total CO2 above
16.5 m under their conditions of dialysis. They are considered
"intolerant" to their dialysis against acetate, that is, submitted
to non-optimal dialysis conditions in regard to their capacity to
metabolize acetate (Fig. 1B).
The theoretical distribution of these groups of patients on a
C02/C02 graph is represented on Figure 1A. Patients of groups
I, II and III should appear on a single line crossing the intercept( total CO2 = 0) at point A above 18.0 m (in fact around 19
to 20 mM). These patients will lose bicarbonate during dialysis
only when their plasma concentration exceeds this equilibrium
point. In contrast, (Fig. 1B) patients of group V will appear on
a different and less steep line, with an intercept lower than 16.5
mM.
Prospective study
Population. In order to validate our indirect indexes of
inappropriate acetate metabolism, a prospective study was
performed. All the 60 patients actively hemodialyzed in our
hospital were studied. Using their past dialysis records, they
were distributed among groups I to V as described above.
Plasma acetate concentration was then measured at the end of
a dialysis treatment when the steady—state acetate concentra-
tion is assumed to be reached in the blood.
Measurements
Blood samples were routinely obtained every other week at
the beginning and at the end of the dialysis procedure. The
clinical biochemistry was that of the hospital laboratory.
Plasma acetate was measured by gas chromatography using the
following procedure: a sample of blood (1 ml) was obtained;
following addition of an internal standard (propionic acid), the
blood was centrifuged and the plasma (100 tl) was deprotein-
ized with metaphosphoric acid. A sample of the supernatant (1
tl) was injected into a Perkin—Elmer gas chromatograph (type
Sigma 1), using a Chromosorb glass column, and the signal was
detected using a flame ionization detector. The retention times
were 1.7 minutes for acetate and 3.1 minutes for the internal
standard. Concentrations were calculated by the peak—height
ratio method.
Statistical analysis
For the retrospective study, least—square linear regressions
were used to calculate the "equilibrium" bicarbonate concen-
tration of each patient. The parameters of this function (slope,
intercept, correlation coefficient) as well as the other biochem-
ical measurements of interest were averaged for each group.
The mean pre- and post-dialysis total CO2 was also computed
for each patient in order to represent each of them as a single
point on a CO2/CO2 graph. All the relevant clinical and
biochemical parameters measured before and after dialysis
were also averaged per groups of 25 hemodialysis patients in
order to describe the evolution of these parameters with time
(CO2 blood urea nitrogen, creatinine, phosphate, calcium, he-
moglobin, hematocrit). These variables were analyzed by vari-
ance analysis (one way) followed by an a posteriori comparison
at each group one with another using the Scheffd procedure. A
two—way variance analysis was also performed to isolate the
sex factor within each group and orthogonal a priori compari-
sons were performed. In the latter analysis the following
comparisons were used: groups 1,2,3, versus 5 (normal vs.
acetate intolerance); 4 versus 5 (uncertain tolerance group vs.
group "intolerant" to their dialysis against acetate); 1 versus 3
(bicarbonate gaining vs. bicarbonate loosing patients) and 1
versus 2 (two subgroups of normal patients). Covariance anal-
ysis relating the changes observed before and after dialysis for
each variable and the effect of sex were also performed. The
distribution of males and females in "tolerant" and "intoler-
ant" groups were tested using a chi—square analysis. The
a-value chosen for all comparisons was 0.01. Unless stated
otherwise, the statistical analysis was performed using the
BMDP statistical software, (University of California, 1983). For
the prospective study, a Student's t-test was used to compare
the end—dialysis plasma acetate in men and women, as well as
to compare the plasma acetate of "tolerant" and "acetate
intolerant" patients.
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Results
Retrospective study
1. The principle of the ACO2/C02 plot as illustrated in
individual patients. An "acetate tolerant" patient. Figure 2A
presents the A total CO2 as a function of the pre-dialysis total
CO2 in a representative normal patient. It can be seen that a
positive A CO2 is usually observed when the initial plasma total
A CO2 is below the intercept value (21 mM), and a negative A
CO2 when above. The calculated intercept (A) matched the
mean bicarbonate concentration observed at the end of dialysis
(P). The magnitude of the A CO2 thus appears to be a direct
function of the initial total CO2: the lower this value below the
equilibrium point (21 mM), the larger the ACO 2 observed. This
indicates that the plasma concentration rises steadily during the
dialysis procedure (and the A CO2 falls) as long as the metabolic
generation of bicarbonate from acetate occurs faster than the
dialyctic loss. These two processes equilibrate when the loss of
bicarbonate increases sufficiently (due to higher plasma total
CO2) to match the metabolic generation of bicarbonate, that is,
the rate of acetate metabolism.
The intercept (A) of the A CO2/CO2 function represents a
convenient parameter to estimate the capacity of this patient to
metabolize the acetate load imposed to him under the dialysis
conditions used. Clearly this value is also a function of the lOss
of bicarbonate per dialysis, and will change if the conditions of
dialysis change (larger surface membrane). Nevertheless, this
index is useful to appreciate the adequacy of acetate metabo-
lism of patients submitted to a given dialysis set—up.
Note that the frequency of hemodialysis where a net loss of
bicarbonate occurs can be directly assessed by counting the
points located at the right of the A CO2 = 0 line. In Figure 2A,
the vast majority of points are in the positive region: a net
bicarbonate loss occurred in only 4% of hemodialysis treat-
ments examined.
An "intolerant" patient. In contrast, Figure 2B presents the
pattern observed in a patient who frequently loses bicarbonate
during dialysis (in 69% of his treatments). His metabolism of
acetate is not rapid enough to offset the dialyctic loss of
bicarbonate occurring when his arterial total CO2 concentration
rises above 15.5 m. Accordingly the slope of the line is less
steep than in Figure 2A. The relation here is less tight because
six years of observation are pooled in one graph; both the
capacity to metabolize acetate and the dialyctic loss of bicar-
bonate may fluctuate with time, and this introduces a variability
when the points are pooled over long observation periods.
Nevertheless, the value of the intercept A coincides reasonably
well with the mean value of post-dialysis total CO2. Since this
patient was dialyzed under conditions identical to those of the
patient described in Figure 2A, a metabolic difference (smaller
weight or slower rate of acetate metabolism) must be invoked to
explain the difference between both responses.
2. Analysis of a population of hemodialyzed patients. The
same relation was computed for the 219 patients studied. The
patients were divided in five groups according to the criteria
defined in the Methods section. The parameters of each group
are presented on Table 1. It can be seen that the mean number
of hemodialysis per patient was above 150 in each group,
indicating that on average each patient was observed for more
than a year, while some patients were studied for 10 years.
For normal patients of groups I, II and III, the two estima-
tions of the equilibrium bicarbonate concentration, that is, the
intercept (A) and the post-dialysis total CO2 (P), are similarly
around 19 to 21 m. The slope of the A C02/CO2 function is also
similar. The major difference between these three groups is the
mean pre-dialysis total CO2. Patients of group I start dialysis
with a total CO2 well below the equilibrium value. This situation
is corrected per dialysis and a large positive A CO2 is observed.
In group II, the pre-dialysis total CO2 is closer to (but generally
below) the equilibrium valve value, and a modest positive A
CO2 is measured. In group III, the pre-dialysis total CO2 is
usually above the equilibrium value, and the A CO2 is thus
negative. Thus, bicarbonate levels above 20 to 21 mM will not
be observed immediately post-dialysis under our conditions.
Accordingly, patients of group I lose bicarbonate in 6% of
dialysis, of group II in 27%, and of group III in 49%. Irrespec-
tive of a net gain or loss of bicarbonate per dialysis, the patients
of these three groups (I, II, III) present the same "equilibrium"
bicarbonate concentration and are thus considered normal.
From the 219 patients studied, 176 (80%) are found in these
normal groups (normal A and P indexes), and this fraction rises
to 90% if the patients of group IV are included (normal P index
only).
In contrast, the 22 patients of group V, mostly women,
present a low initial total CO2 (lower than in group I) but fail to
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Table 1. Net gain or loss of plasma, total CO2 in 221 patients dialyzed against acetate
C02/C02 Relation
Number of
Number of points mea- Intercept Correlation
patients per Females/Males sured per Slope A coefficient
Groups group % of female patient B mM r
I 63 13/50
21%
88 12 0.516 0.030 19.5 0.24 0.488 0.022
II 95 36/58
41%
69 8 0.477 0.026 19.2 0.21 0.510 0.021
III 21 8/13
38%
38 12 0.527 0.107 20.1 0.39 0.498 0.056
IV 19 10/9
53%
91 22 0.259 o.o38c' 15.7 023cf,h 0.205 0.039"
V 22 19/3
87%°
44 7 0.361 0042k 15.2 031d,g,i,k 0.418 0.038
Data are mean SEM. The groups were compared by one way variance analysis followed by the Scheffé procedure comparing a posteriori each
group one with another. An a-value of 0.01 was chosen. Each comparison is defined by a letter: I vs. 2 = "; I vs. 3 = b; I vs. 4 = '; 1 vs. 5 = 'i'; 2 vs.
3 = a. 2 vs. 4 f; 2 vs. 5 =g; 3 vs. 4 = h; 4 vs. 5 = 1; 3 vs. 5 = . A two—way variance analysis was also performed to isolate the sex factorwithin each
group. None of the data presented on this table were significantly different in males and females. The a priori orthogonal comparisons chosen were
1, 2, 3 vs. 5 = k; 4 vs. 5 = I; 1 vs. 3 = m. I vs. 2 = ". To compare the sex distribution within "tolerant" and "intolerant" groups a chi—square analy-
sis was chosen testing 1, 2, 3, 4 vs. 5 = 0.
gain bicarbonate per dialysis, and even exaggerate their acido-
sis in more than 50% of the hemodialysis examined (Table 1,
Fig. 1B). Both their A and P values are lower (below 16.5 mM)
than the values noted in normal patients (groups I to III).
Clearly, under the conditions of dialysis used, these patients are
not able to generate enough bicarbonate from acetate metabo-
lism to replace the bicarbonate lost through dialysis when the
plasma bicarbonate exceed 15mM. Accordingly the slope of the
A C02/C02 graph computed for these patients is significantly
lower than that observed in normal patients (Table 1). Note that
the averaged number of hemodialysis in this group was 155, that
is, these patients were dialyzed for a shorter period than those
of groups I to III (162 to 359 dialysis). Since the end—dialysis
plasma acetate concentration is higher in patients of this group
than it is in normal patients, it is probable that their maximal
rate of oxidation was lower than the patients from groups I to
IV. Increasing the acetate concentration in the dialysate is not
expected, therefore, to correct this problem and may lead solely
to a further increase in circulating acetate concentration.
Group IV (Table 1) presents 21 individuals presenting a low
intercept value (A < 16.5 mM) but a normal post-dialysis total
CO2 value (P) (P > 16.5 mM). This group thus stands in
between normal and abnormal patients. However it contains all
patients where the correlation coefficient of the A C02/C02
relationship is poor; the least—square estimation of both slope
and intercept of this function are less reliable (Table 1). Because
their end-dialysis total CO2 (P) is around 18.0 mM those
patients were considered normal. However, it is possible that
some patients with less severe defect in bicarbonate generation
may also be included in this group.
If each of the 219 patients studied (groups I to V) is repre-
sented as a single point (using their mean pre- and post-analysis
total CO2) on a A CO2/CO2 graph including the whole popula-
tion (Fig. 3), it is clear that the population identified as group V
is located below the normal patients (groups I—IV).
From Figure 3 and Table 1 the following conclusions can be
drawn: 1) in a general population of hemodialyzed patients,
around 10% (22 of 221) are routinely unable to generate bicar-
bonate optimally when dialyzed against acetate using standard
conditions; 2) this anomaly is seen mostly in female patients (19
of 22); and 3) a progressive decrement of the capacity to
metabolize acetate as a function of the duration of hemodialysis
treatment does not seem to be responsible for this anomaly
since the patients of group V were not dialyzed for longer
periods than those of groups Ito III.
3. Analysis of various factors possibly related to "intoler-
ance" of dialysis against acetate.
Duration of dialysis. Because "acetate—intolerance" has
been shown to be acquired in some patients [16], the capacity to
metabolize acetate with time was examined. If "acetate—
intolerance" is an acquired anomaly, it is expected that both
estimations of the "equilibrium" total CO2 concentration A and
P should decrease with time. To assess this we have followed
the P value (averaged per groups of 50 dialysis treatments) as a
function of time in each group of patients. Figure 4A shows that
for patients of group I, the pre- and post-dialysis bicarbonate
concentration form two parallel horizontal lines when plotted
for up to 10 years (1500 dialysis) of observation, the post-
dialysis value (20 mM) being above the pre-dialysis value (16
mM). The same graph calculated for patients of group V is
depicted in Figure 4B. The situation is similar except that the
two lines are now superimposed around 15 mM. Thus most of
the "intolerant" patients showed their defect right at the
beginning of dialysis treatments.
Metabolic acidosis. In order to evaluate if the initial degree of
acidosis could have interfered with the capacity of patients of
group V to metabolize acetate, we selected from the 63 patients
of group I, the individuals with a low (<16 mM) pre-dialysis
total CO2 concentration. A group of 30 patients was obtained
with a mean initial total CO2 of 14.8 0.15 mM, a value
identical to that observed in group V (15.3 0.38 mM).
However the mean A CO2 of this group was +5 mM, in contrast
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Table 1. Continued
% of dialysis with
negative CO2 I %
Pre-dialysis total
CO2 mM
Post-dialysis total
CO2 P mM
Post-dialysis
CO2 mM
Number of
hemodialysis
per patient
6.0 0.4 17.3 0.24 21.3 0.22 +4.0 0.12 359 45
26.5 l.3a.n 18.4 0.2l 20.3 O2O +1.8 0.l2a 283 30
48.2 48c,f,h,n 21.1 038b, 19.9 045b,m —1.2 024b,,h,n 166 59
19.9 34b is.i o.38" 18.4 0.30 +3.3 o.45f 382 94
53.3 3•6d 15.3 038d.g,j 14.8 038d,g..k.I —0.5 024d.g,f,k,I 159 32
0
—8
x Co2
Total CO2 mM
Fig. 3. On this plot, each patient of the study is represented by a single
point calculated from his mean total CO2 concentration before and
after dialysis. The normal population (groups I to IV) is represented as
closed circles while the intolerant population (group V) is represented
as open circles. The lines were calculated by least—squares regression
analysis.
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Fig. 4. The mean plasma total CO2 before (open symbols) and after
(closed symbols) dialysis were averaged by groups of 50 consecutive
hemodialysis and presented as function of the number of treatments to
show the effect of time on these parameters. A. The data of the normal
patients of group I, while B shows the data of the intolerant group V.
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with the value of group V (—0.5 mM). We concluded that the
initial degree of acidosis was not responsible for the defect
observed in the patients of group V.
Inadequate dialysis. To explore if this defect could be related
to the presence of dialyzable factors (uremic toxins) in the
plasma affecting the metabolism of acetate we have compared
various indexes of hemodialysis quality in the five groups: the
mean pre- and post-dialysis values for creatinine, blood urea
nitrogen, etc., were identical (Table 2). Furthermore, if uremia
was in part responsible for the abnormal metabolism of acetate,
we would expect to see an increment of the P value during the
first 50 treatments when dialysis progressively corrects part of
the uremic state. This was not the case (not shown).
Small muscle mass. Table 2 demonstrates also that the
inability of the patients of group V to metabolize acetate
normally was not related solely to a smaller muscle mass since
their pre- and post-dialysis body weight and their mean incre-
ment of plasma creatinine between dialysis was comparable to
that of normal groups I to III.
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Table 2. Clinical and biochemical data of 221 chronically hemodialyzed patients
Groups 1 11 111 lv V
Number of patients 63 95 21 19 22
Weight, kg
before 64.9 1.49 60.8 1.43 61.8 2.71 57.5 2,35 58.5 2.98
after 63.3 1.48 59.5 1.41 60.6 2.57 56.0 2.24 57.5 2.98
Blood pressure, mm Hg
Systolic
before 152 2.4 153 1.7 151 5.6 145 4.1 153 4.2
after 146 2.2 148 1.9 146 6.1 139 4.8 152 4.1
Diastolic
before 86 1.4 86 1.0 82 2.2 81 1.9 81 2.2
after 82 1.3 83 1,0 79 2.6 78 2.1 81 1.9
BUN, mgldl
before 90 2.3 89 1.8 76 4.4° 92 4.2 lOl 6.8
after 44 1.3 45 1.1 39 2.0 43 3.0 51 4.9'
Creatinine, mgld!
before 13.4 0.40 12.0 0.26 11.5 0.66 13.0 0.66 10.9 054d
after 7.3 0.23 6.6 0.16 6.5 0.41 6.8 0.45 5.9 0.25i
Phosphate mgldl
before 5.3 0.12 5.1 0.09 5.0 0.23 5.7 0.23 5.2 0.23
after 3.3 0.06 3.1 0.05 3.1 0.13 3.3 0.13 3.0 0.11
Calcium mgld/
before 8.7 0.09 8.8 0.07 8.8 0.20 8.8 0.26 8.5 0.12
after 9.9 0.09 9.9 0.07 9.9 0.17 10.2 0.25 9.8 0.11
Hemoglobin gid!
before 7.2 0.17 7.2 0.12 7.3 0.20 7.4 0.34 7.3 0.21
after 7.7 0.18 7.7 0.13 7.7 0.95 8.0 1.66 7.9 1.18
Hematocrit, %
before 21.9 0.49 22.0 0.35 22.4 0.61 22.7 0.85 22.2 0.60
after 23.0 0.53 23.1 0.37 23.6 0.63 24.2 1.04 23.8 0.72
The data are mean SEM of the values measured before and after dialysis. All measurements post-dialysis were significantly correlated to the
pre-dialysis values (covariance analysis) P <0.01. Analysis for the effect of sex using a two—way variance analysis demonstrated that the women
weighed less and had lower concentrations of BUN, creatinine and phosphate than men (P < 0.01). j,d,, are the same as in Table 1.
It can be concluded that the abnormal capacity to metabolize
acetate appears to be an individual characteristic that remains
for the whole period of dialysis using acetate. This is not to say
that the capacity for acetate metabolism remains unchanged at
all time. Indeed transient, but often severe, exaggeration of
metabolic acidosis per dialysis due to abnormal loss bicarbon-
ate (rapid hemofiltration) or to transient impairment of the
capacity to metabolize acetate, can be observed in patients with
acute conditions such as myocardial infarction or acute infec-
tion. This is illustrated in Figure 5 for a patient following an
unsuccessful transplant.
Prospective study
If the rate of acetate metabolism is not optimal in patients of
group V, it is expected that they should present a plasma
acetate concentration higher than normal patients at the end of
dialysis. In order to validate our indirect indexes of "acetate
intolerance," we measured the end—dialysis plasma acetate in
the 60 patients under active hemodialysis in our hospital. Using
the criteria described above, these patients were divided into
"normal" (groups Ito IV; N = 48) and "abnormal" (group V;
N = 12)patients. As shown on Table 3 the mean plasma acetate
observed in normal male patients was lower than the value
observed in normal female patients. The "acetate intolerant"
patients (11 females, 1 male) presented a plasma concentration
higher than "tolerant" patients (Fig. 6). This suggests, there-
fore, that increasing the acetate concentration in the dialysate
would not improve the rate of bicarbonate generation in these
patients, but would simply further increase their circulating
acetate concentration. Not shown in the figure, four patients
with normal indexes (computed over several months of obser-
vation) also presented high plasma acetate when studied (be-
tween 7 and 10 mM). These patients were acutely ill at the time
of the study (1 post-unsuccessful transplant, 2 severe angina,
and 1 septicemia). We concluded that they presented a second-
ary and transient inability to metabolize acetate optimally that
was not reflected in their blood analysis previous to the acute
episode.
Discussion
The measurement of the "equilibrium" plasma total CO2
concentration per—dialysis is a good index of the acid—base
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Table 3. Measurement of equilibrium total CO2 and plasma acetate at
the end of hemodialysis in 56 active patients
Equilibrium
A
m
total CO2
P
mM
Plasma
acetate
mis
Body
wt
kg
Acetate tolerant
Men N = 28 18.9 20.2
0.27
1.75 63.8
Women N= 16 18.2 19.2 272b 56.0
Acetate intolerant
Men N = 1 13.8 15.5 8.0 53.0
Women N = 11 15.4 15.1
0
00
it
Time, days
Fig. 5. The occurrence of an acute intolerance to acetate in a patient
following surgery. This is evidenced by the severe worsening of
acidosis post-dialysis. Each point represents a consecutive dialysis.
Symbols are: (O---O) before HD; (—•) after HD.
tolerance of a given patient to dialysis using acetate as a source
of bicarbonate. Indeed, this value reflects the combined pro-
cesses of bicarbonate losses through dialysis and ultrafiltration
on the one hand, and metabolic generation of bicarbonate
through acetate metabolism on the other hand. The latter
process is limited by the maximal rate of acetate oxidation in
man (4.5 mmoL/hr/kg in normal man [17—191 and between 2.5
and 3.5 mmol/hr/kg in dialyzed patients [3—5, 201.1 Since the rate
of acetate metabolism (and bicarbonate generation) necessary
to maintain plasma bicarbonate around 20 mM during conven-
tional hemodialysis approaches this maximal rate [3—51, (which
may change from patient to patient), this factor becomes critical
for acid—base tolerance to dialysis.
In any dialysis conditions, plasma bicarbonate determines in
part the dialyctic losses of bicarbonate. In turn, with dialysis
S
0
Data are mean SEM
A, intercept of the C02/C02 relation; P post-dialysis total CO2
IC Different from men, P < 0.05
C different from tolerant women, P < 0.05
Men Women
(29) (27)
P< 0.01
p.rzo.Oi 26
10
'r
8
1 -
6 S
8
4 +
Intolerant Tolerant
N=1 N=16
Fig. 6. The plasma concentration of acetate measured at the end of
hemodialysis in patients identified as "tolerant" or "intolerant" to
acetate using the indirect criteria defined in this study.
against acetate, the plasma bicarbonate is fixed by the meta-
bolic rate of bicarbonate generation; the faster the acetate
metabolism and generation of bicarbonate the higher the plasma
concentration of bicarbonate, and also the greater the losses
through dialysis. Therefore, change in plasma bicarbonate will
automatically adjust the net dialyctic loss of bicarbonate to
match the rate of metabolic generation of bicarbonate. Assum-
ing comparable dialysis conditions the "equilibrium" plasma
bicarbonate—concentration per dialysis is thus a direct function
00I
C Vreman et al [20] have found higher rates of acetate metabolism in
some patients by analyzing the kinetics of disappearance of acetate
from plasma following hemodialysis. It is not clear, however, if the rate
observed at this time of the dialyctic cycle is not modified by superim-
posed compartmental redistribution of acetate.
1202 Vinay et a!
Table 4. Factors influencing the rate of acetate metabolism in man
1. Acetate load
2. Sex
3. Age
4. Muscle mass
5. Alternative substrates (diabetes, ketosis, proteolysis)
6. Hypoxia, delivery of oxygen to tissues
7. Delivery of acetate to tissues: hemodynamics
of the capacity of a given patient to metabolize a given acetate
load.
Clearly, the use of a surface membrane too large for the body
mass of a patient with normal acetate metabolism may prevent
the full correction of acidosis during dialysis, or even worsen
the acidosis by imposing a large loss of bicarbonate while
simultaneously providing acetate at a rate exceeding the meta-
bolic capacity of this patient [6—8]. Alternatively, a patient
dialyzed in usually optimal fashion may present an abnormally
slow rate of acetate metabolism, and may be unable to face the
usual bicarbonate losses per hemodialysis without developing a
metabolic acidosis [9]. Acetate will then accumulate in the
blood, and a large alkaline rebound will be observed post-
dialysis when the dialyctic bicarbonate drain no longer exists [4,
20].
In both circumstances, a low intercept (A) will be found on a
CO2/CO2 graph as well as a low post-dialysis total CO2
concentration (P). Thus these indexes, like the measurement of
the end—dialysis ("equilibrium") plasma acetate—concentration,
only provide evidences for the existence of an imbalance
between the rate of acetate metabolism and the rate of bicar-
bonate loss. This imbalance, together with non-specific symp-
toms attributed in part to the pharmacologic effect of acetate at
high concentration, have provided the basis for the so—called
"acetate intolerance syndrome" [10]. Clearly, this imbalance is
not obligatorily related to a specific biochemical anomaly of
acetate metabolism since some patients may present this defect
solely due to their small body mass.
In this study, we have taken advantage of the indirect indexes
A and P to screen a large population of chronically
hemodialyzed patients for "acetate intolerance." Ten percent
of the population was clearly unable to metabolize acetate fast
enough to maintain plasma bicarbonate per dialysis above 15
mM when submitted to standard dialysis conditions. The con-
ditions of hemodialysis being roughly comparable for all pa-
tients, the cause of "acetate intolerance" must be looked for in
the patients themselves.
Factors influencing acetate metabolism
Sex. The capacity to metabolize acetate is dependent upon
various factors listed in Table 4. The first factor to consider is
muscle mass. Indeed, acetate is rapidly oxidized by the muscle
[19, 21, 22] which may be its major site of utilization. In our
prospective study, the end—dialysis plasma acetate concentra-
tion is higher in normal female than in normal male patients. We
have attributed this observation to the sex difference in muscle
mass. The difference is only modest, however, and induces a 1
mM difference in the final concentration of bicarbonate post-
dialysis, not the 5 mM observed in our intolerant group.
Therefore, even if a strong predominance of intolerance is seen
in female patients (P < 0.01), the anomaly cannot be explained
by the sex difference alone.
Muscle mass. It would have been possible also that our group
of intolerant patients was composed of individuals with small
muscle mass. In the original report of acetate intolerance by
Novello, Kelsh and Esterling [9], the problem occurring in
some cases (children) was probably related to their small body
weight. In our study however, two indexes of muscle mass, that
is, the body weight and the increment of plasma creatinine
during the interdialyctic interval, were comparable in "acetate
tolerant" and "acetate intolerant" groups.
Age. It has been reported that age was influencing the
capacity to metabolize acetate [8]. It is probable that this effect
reflects the reduction in muscle mass occurring with aging. Our
intolerant group was not older, but somewhat younger than the
controls.
Diabetes. Metabolic anomalies such as diabetes has been
shown to influence acetate metabolism [21]. It is unlikely that
this could be the factor here since a similar modest
hyperglycemia were evident in all our patients irrespective of
tolerance or intolerance to acetate. Furthermore, all our pa-
tients were dialyzed against glucose—free dialysate, and were
therefore not hyperglycemic during their dialysis.
Uremia. Uremia has been shown to alter the maximal rate of
acetate metabolism [3—61. Change in muscle mass may be in
part responsible for this phenomenon, but specific effects are
possible. Egan and Wells reported a patient who became
acetate intolerant after several years of dialysis, and who
presented a circulating inhibitor of acetate oxidation by leuko-
cytes in vitro [16]. If "uremic toxins" were responsible for this
syndrome, it should prevail amongst patients poorly dialyzed,
or dialyzed for prolonged periods. This was not the case for our
"intolerant" patients which were dialyzed for shorter periods
than those of the control group I, and were already "acetate
intolerant" at their first hemodialysis.
Oxygen and acetate availability. Acetate has a strictly aero-
bic metabolism. Therefore, its rate of oxidation is critically
dependent upon the delivery of both acetate and oxygen to
peripheral tissues [21]. A hypoxia of moderate amplitude is
usually present at the beginning of dialysis with acetate and
attributed to the combined effects of decreased pulmonary
ventilation (secondary to CO2 losses through the dialyzer) and
of reduced CO2 production when acetate is the predominant
oxidative fuel [reviewed in 23]. It is improbable that hypoxia
alone could be responsible for the intolerance observed here
because hypoxia is routinely observed during the first minutes
of dialysis in most patients, irrespective from their tolerance to
acetate. Furthermore, although we have not measured arterial
P02 during hemodialysis in a systemic fashion, our "intoler-
ant" patients were frequently given 02 (28%) during dialysis
because of fluctuating symptoms which could be in part attrib-
utable to hypoxia. No dramatic improvement in their symptoms
[24] nor increment of their end-dialysis bicarbonate concentra-
tion was observed.
The rise in blood acetate may itself depress acetate metabo-
lism by creating a vasodilation [10—12] in splanchnic vascular
beds and so reducing muscular perfusion. The vasodilating
effect of acetate has been attributed to the local formation of
adenosine following the metabolism of acetate [25].
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Acetate + ATP + COA —* AcetylCoA + AMP + PPI
(acetylCoA synthetase)
AMP
—adenosine (5 nucleotidase)
This vasodilating effect may be potentiated by hyposomolar-
ity [26, 27] and partially reversed by raising the sodium con-
centration in the dialysate [27]. It is thus possible to hypothe-
size that the syndrome could be in part related to an abnormal
vascular sensitivity to adenosine. The conjunction of such an
effect with a smaller muscle mass (as found in women) could
explain both the increased episodes of hypotension and the
biochemical anomalies of this syndrome.
Alternative substrates. Finally, it should be noted that the
maximal rate of acetate oxidation may change if alternative
substrates are provided. Indeed, it has been shown that acetate
becomes the major metabolic fuel during hemodialysis [4, 5,
28]. This implies that acetate has displaced the endogenous
substrates previously metabolized. A similar situation is also
observed in vitro [29]. It may therefore be envisaged that the
maximal rate of acetate oxidation could not be reached if
alternative substrates such as ketone bodies (ketosis), lactic
acid (lacticidemia) or aminoacids (severe proteolysis) are simul-
taneously available in large quantity. These transient anomalies
however could not explain the stable acetate intolerance ob-
served in 10% our hemodialyzed patients.
On the other hand, and as shown in this study, previously
normal patients may become temporarily incapable of metabo-
lizing acetate normally if they become acutely cachectic (loss of
muscle mass), if they develop severe perfusion defects due to
vascular instability (left heart failure, severe angina), or if they
become acutely ill with septicemia inducing a severe
proteolysis. This transient intolerance syndrome will disappear
when the muscle mass is regained, when the ventricular func-
tion improves, or when the septic proteolysis is corrected.
Our study, therefore, supports the concept that as far as the
acid—base status is concerned, chronic hemodialysis with ace-
tate is a suboptimal but acceptable treatment for 90% of uremic
patients. This number will be reduced if the concentration of
acetate is increased above 38 to 40 mM in the dialysate or if a
membrane with larger surface area was used. Indeed, the
end—dialysis bicarbonate concentration in "normal" patients is
20 to 21 mM, that is, well below the physiological concentration
(24 to 26 mM). This indicates that even in optimal conditions,
dialysis against acetate is not able to fully correct the acidosis of
uremic patients and this pleads for the use of dialysis against
bicarbonate whenever possible. Furthermore, 10% of the pa-
tients, mostly females, cannot be dialyzed satisfactorily using
acetate and should be placed on bicarbonate dialysis. These
individuals can be identified by a simple procedure as shown in
the present study. Furthermore, because "acute intolerance"
to acetate readily occurs, it seems safer to always use dialysis
against bicarbonate for acutely ill patients, even if they were
chronically dialyzed successfully with acetate prior to their
acute illness. This principle is in accord with the opinion of
others [15].
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